Menopause hormone replacement therapy: Controversial accuracy and outlook issues;Tratamiento hormonal de la menopausia: Controversias, precisiones y perspectivas

Medicina Clinica

Volumn 120, Issue 4, 2003, Pages 148-155

  Pérez López, Faustino R ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Bisphosphonates; Breast cancer; Breast density; Cardiovascular disease; Estrogen; HERS; Hormone replacement therapy; HRT; Osteoporosis; Phytoestrogens; Progestine; Raloxifene; Tibolone; Tromboembolic disease; WHI

Indexed keywords

CALCIUM; CLONIDINE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN; PAROXETINE; PHYTOESTROGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TIBOLONE; VENLAFAXINE; VERALIPRIDE; VITAMIN D;

ACCURACY; ATHEROSCLEROSIS; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CLIMACTERIUM; COLON CANCER; ENDOMETRIUM CANCER; EXERCISE; FEMALE; GENITAL BLEEDING; GYNECOLOGY; HORMONE SUBSTITUTION; HUMAN; LIVER DISEASE; MEDICAL LITERATURE; MENOPAUSAL SYNDROME; MENOPAUSE; MORTALITY; NEUROLOGIC DISEASE; OBSTETRICS; OSTEOPOROSIS; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0037425891     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13042990     Document Type: Review

References (62)

1. Wilson RA. Feminine forever. New York: M. Evans and Company Inc., 1968.
2. Foucault M. The birth of the clinic: an archeology of medical perception. New York: Vintage Books, 1975.
3. Greer G. The change. Women, ageing and the menopause. London: Penguin Books, 1992.
4. Vanwesenbeeck I, Vennix P, Van de Wiel H. «Menopausal symptoms»: associations with menopausal status and psychosocial factors. J Psychosom Obstet Gynaecol 2001;22:149-58.
5. Petitti DB. Hormone replacement therapy for prevention: more evidence, more pessimism. JAMA 2002;288:99-101.
6. Fletcher SW, Colditz GW. Failure of estrogen plus progestin therapy for prevention. JAMA 2002;288:365-8.
7. Stevenson JC, Whitehead MI. Hormone replacement therapy. BMJ 2002: 325:113-4.
8. Day A. Lessons from the Women's Health Initiative: primary prevention and gender health. CMAJ 2002;167:361-2.
9. Neves-e-Castro M, Samsioe G, Doren M, O Skouby S. Results from WHI and HERS II - Implications for women and the prescriber of HRT. Maturitas 2002;42:255-8.
10. Balasch J. Terapéutica hormonal sustitutiva como prevención en la posmenopausia: ¿lin de la controversia? Med Clin (Barc) 2002;119:416-7.
11. The North American Menopause Society. Use of hormone replacement therapy questioned for some women. A preliminary response from the North American Menopause Society. [consultado 21/8/2002]. Disponible en: http://www.menopause.org/pr.html#pr15
12. British Menopause Society. USA Women's Health Initiative Oestrogen plus Progestogen HRT study terminated early. [consultado 21/8/2002]. Disponible en: http://emas.obgyn.net/about.asp?page=UK-GreatBritain
13. ACOG News release. For Release July 9, 2002 Statement on the Estrogen Plus Progestin Trial of The Women's Health Initiative by The American College of Obstetricians and Gynecologists [consultado 21/8/2002]. Disponible en: http://www.acog.org/from_home/publications/press_releases/nr07-09-02.cfm
14. Pérez-López FR. Longevidad, climaterio y envejecimiento. En: Pérez-López FR, editor. Climaterio y envejecimiento: Medicina basada en la evidencia. Zaragoza: SEISGE, 1999; p. 1-14.
15. Pérez-López FR. La menopausia: cómo vivirla y superarla sin miedo. Madrid: Temas de Hoy, 1992.
16. Carrasco P, Astasio P, Ortega P, Jiménez R, Gil A. Factores asociados al consumo de fármacos psicotropos en la población adulta española. Datos obtenidos a partir de las Encuestas Nacionales de Salud de España de los años 1993, 1995, 1997. Med Clin (Barc) 2001;116:324-9.
17. Keating N, Cleary P, Aossi A, Zaslavsky A, Ayanlan J. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999;130:545-53.
18. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 2001;76:231-8.
19. Greendale GA, Reboussin BA, Hogan P, Barnabei VM, Shumaker S, Johnson S, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/progestin Interventions (PEPI) Trial. Obstet Gynecol 1998;92:982-8.
20. Mac Lennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric 2001;4: 58-74.
21. Hollander LE, Freeman EW, Sammel MD, Berlin JA, Grisso JA, Battistini M. Sleep quality, estradiol levels, and behavioral factors in late reproductive age women. Obstet Gynecol. 2001;98:391-7.
22. Antonijevic IA, Stalla GK, Steiger A. Modulation of the sleep electroencephalogram by estrogen replacement in postmenopausal women. Am J Obstet Gynecol 2000;182:277-82.
23. Zweifel JE, O'Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 1997; 22:189-212.
24. Pérez-López FR. Los andrógenos en la mujer menopáusica. Med Clin (Barc) 2003;120:31-6.
25. Schmidt PJ, Nieman L, Danaceau MA, Tobin MB, Roca AC, Murphy JH, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000:183:414-20.
26. Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: A double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001; 58:529-34.
27. Pérez-López FR. Urogenital alterations during Menopause and estrogen therapy. Menopause Review 2002;7:45-55.
28. Díaz Curiel M, García JJ, Carrasco JJ, Honorato J, Pérez Cano R, Rapado A, et al. Prevalencia de la osteoporosis determinada por densitometría en la población femenina española. Med Clin (Barc) 2001;116: 86-8.
29. Wu F, Ames R, Clearwater J, Evans MC, Gamble G, Reid IR. Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women, including the effect of hormone replacement therapy. Clin Endocrinol 2002;56:703-11.
30. Greendale GA, Espeland M, Slone S, Marcus R, Barrett-Connor E. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Arch Intern Med 2002;162:665-72.
31. Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of non-vertebral fractures. A metaanalysis of randomised trials. JAMA 2001;285:2891-7.
32. Writing group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288;321-33.
33. Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 2001;86:4717-26.
34. Pérez-López FR, Cuadros JL. THS y aparato digestivo, respiratorio y ojo. En: Asociación Española para el Estudio de la Menopausia, editor. Medicina basada en la evidencia en menopausia. Madrid: EFFIK, 2002; p. 291-308.
35. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al, for the HERS Research Group. Heart and estrogen/progestin replacement study follow-up (HERS II): Part 1. Cardiovascular outcomes during 6.8 years of hormone therapy. JAMA 2002;288:49-57.
36. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A Clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-9.
37. Hu FB, Grodstein F. Postmenopausal hormone therapy and the risk of cardiovascular disease: the epidemiologic evidence. Am J Cardiol 2002; 90(Suppl 1):F26-9.
38. Gambacciani M, Ciaponi M, Cappagli B, De Simone L, Orlandi R, Genazzani AR. Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas 2001;39:125-32.
39. Pérez-López FR. Obesidad, climaterio y tratamiento hormonal de reemplazo. Boletín de la Asociación Española para el Estudio de la Menopausia 2001;3:7-12.
40. Schairer C, Lupin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-91.
41. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-32.
42. Magnusson C, Persson I, Adami H-O. More about: effect of hormone replacement therapy on breast cancer risk: risk; estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:1183-4.
43. Woloshin S, Schwartz LM, Welch HG. Risk charts: putting cancer in context. J Natl Cancer Inst 2002;94:799-804.
44. Sibbald B. Fallout from JAMA's HRT study continuing to land in MDs' offices. Canad Med Ass J 2002;167:387.
45. Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 2001;8:245-51.
46. Cline JM, Soderqvist G, Von Schoulz E, Skoog L, Von Schoulz B. Effect of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996; 174:93-100.
47. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-65.
48. Pérez Sanz R, Villavieja L, De la Cueva P, Morollón I, Pérez-López FR. Mammary changes during the menopausal transition. En: Genazzanni AR, Petraglia F, D'Ambrogio G, Genazzani AD, Artini PG, editors. Recent developments in gynecology and obstetrics. London: The Parthenon Publishing Group, 1996; p. 393-9.
49. Boyd NF, Lockwood GA, Martin LJ, Knight JA, Jong RA, Fishell E, et al. Mammographic densities and risk of breast cancer among subjects with a family history of this disease. J Natl Cancer Inst 1999;91:1404-8.
50. Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999;130:262-9.
51. Pérez-López FR. Breast cancer and hormone replacement therapy: putting the risk into context. En: Rozenbaum H, editor. Proceedings of the First Congress of National European Menopause Societies. Paris: Editions ESKA, 2001; p. 117-35.
52. Pérez-López FR. Mammary changes during menopause and conventional hormone replacement and tibolone therapy. Menopause Review 2002;7:25-36.
53. Chandra NC, Ziegelstein RC, Rogers WJ, Tiefrenbrunn AJ, Gore JM, French WJ, et al. Observations of the treatment of women in the United States with myocardial infarction: a report from the National Registry of Myocardial Infarction-I. Arch Intern Med 1998;158:981-8.
54. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-11.
55. Mosca L. The role of hormone replacement therapy in the prevention of postmenopausal heart disease. Arch Intern Med 2000;160:2263-72.
56. Cushman M. Effects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulation. Am J Cardiol 2002;90:7F-10F.
57. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, et al, for the Estrogen in Prevention of Atherosclerosis Trial (EPAT) Research Group. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-53.
58. Lawlor DA, Ebrahim S, Smith GD. Sex matters: secular and geographical trends in sex differences in coronary heart disease mortality. BMJ 2001;323:541-5.
59. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:273-84.
60. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001;65:125-34.
61. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, et al, for the MORE Investigators. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-57.
62. Rubin LA, Hawker GA, Cole DEC, Peltekova V, Fielding L, Ridout R. Determinants of peak bone mass: clinical and genetic analyses in a young female Canadian cohort, J Bone Miner Res 1999;14:633-43.